We leverage health prediction algorithms across healthcare ecosystem
Howard W. Sams
Chief Executive Officer
Previously Global Head of Siemens Digital and Computational Pathology business. Global leadership roles in Roche Diagnostics over a decade. Multiple roles at Guidant/Boston Scientific, started career at Conseco. BS, Butler University & MBA from the University of Notre Dame.
Leena Das-Young, PharmD
Chief Innovation Officer
Previously was Head of early cancer detection at Guardant. Former Head of Late Phase Oncology Development at Pfizer. Prior global leadership roles in commercial and product development at Pfizer and Bayer. BS in Pharmacy and PharmD from Purdue University.
SVP, Longevity Markets
Leads our Longevity verticals. Previously worked in investment banking and raised capital at JPMorgan, ABN Amro and BlueCrest. MBA, Columbia Business School. BA, Harvard.
SVP, Health Markets
Dan Lewis was COO of The MetroHealth System, a major provider in Ohio, from 2014 to 2018. From 2018 to 2021 he ran Lobesity, a biotech company, through its successful trade sale. Dan received a BA from Kent State and an MA from The Univ of Akron.
Santiago Naranjo, Ph.D.
Oversees proteomic assays and technologies for Health Outlook. Previously worked at Flagship Pioneering. Received his Ph.D. in cancer biology from MIT in 2020.
Tim Opler, Ph.D.
Partner at Torreya, former professor and entrepreneur. Serves on boards of multiple private companies. Previously at Credit Suisse in healthcare investment banking and at FibroGen in a strategy role Ph.D., Econ, UCLA.
Advisor, Health Markets
Heads the Rand Corporation Heath Advisory Board. Banker at Solomon Partners. Former fund manager and long-time investment banker. Received MBA from Wharton.
Manages joint ventures for Health Outlook and project manager for laboratory operations. Previous roles at Essential Data, AccurexDx and Yale University. BA, University of Bridgeport.
Tal Zaks, M.D., Ph.D.
Former CMO, Moderna; Orbimed
Tal Zaks is a Venture Partner at Orbimed and was most recently the Chief Medical Officer of Moderna. Previously, he was head of Global Oncology at Sanofi. Dr. Zaks was also associate professor of medicine at the University of Pennsylvania. Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University.
Peter Koerte, Ph.D.
Chief Technology & Strategy Officer, Siemens
As CTO and CSO for Siemens AG, Peter is responsible for strategy, digitization and establishment of the industrial internet of things (IoT). Peter has had multiple global management roles at Siemen Healthineers and has also worked at BCG. He received a Ph.D. in strategy and international management from WHU Otto Beisheim School of Management. He serves on the board of directors for Health Outlook.
Joseph Konowiecki, J.D.
As General Counsel for PacifiCare, one of the nation's largest health organizations, he was instrumental in closing its $9.2 billion sale to United Health. He is currently Chairman of Alignment Healthcare, a rapidly growing Medicare insurer. He serves on the board of directors for Health Outlook.
Andy Dannenberg, M.D.
Former Prof. Medicine, Weill Cornell Medical College
Partner at Emerald Bioventures. Formerly was Professor of Medicine at Weill Cornell Medical College. Author of 200+ scientific publications. Expert on inflammation and cancer. MD Wash U., St. Louis.
Paul Ridker, M.D.
Prof of Medicine, Harvard University
Dr. Ridker is a cardiovascular epidemiologist and biomedical researcher whose research has provided proof-of-principle for the inflammation hypothesis of atherosclerosis and the first proven anti-inflammatory treatment for coronary artery disease.
David Shulkin, M.D.
Former Secretary, Veterans Admin.
Dr. Shulkin is an American physician and former U.S. Secretary of Veterans Affairs. Shulkin was also CEO of Beth Israel Medical Center and was president of Morristown Medical Center. He was the first CMO of the University of Pennsylvania Hospital.
Co-Founder and Advisor, Torreya
Mark Simon is a partner at Torreya Partners, which he co-founded in 2007. He brings over 20 years of experience in advising biotech companies. He is active on numerous boards including that for the Alliance for Aging Research. Before Torreya, Simon in investment banking at Citigroup and Robertson Stephens. Mark received an MBA from Harvard Business School.
Richard Ulevitch, Ph.D.
Dept. Immunology, The Scripps Research Institute
Richard Ulevitch is professor of immunology and Chairman Emeritus of the Department of Immunology at The Scripps Research Institute. His career is marked by a number of seminal scientific discoveries in the field of innate immunity. He has a strong ongoing interest in implications of proteomics for science and medicine. He received a Ph.D. in Immunology from the University of Pennsylvania.